MK-4280-001, NCT02720068: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors |
|
|
| Completed | 1 | 482 | NA | Favezelimab, MK-4280, Pembrolizumab, MK-3475, KEYTRUDA®, Oxaliplatin, ELOXATIN®, Irinotecan, CAMPTOSAR®, Leucovorin (Calcium Folinate), WELLCOVORIN®, Fluorouracil [5-FU], ADRUCIL®, Favezelimab/Pembrolizumab, MK-4280A, Lenvatinib, E7080, MK-7902, LENVIMA® | Merck Sharp & Dohme LLC | Neoplasms | 03/24 | 03/24 | | |
